Keyphrases
Growth Factors
100%
Insulin-like
100%
Human Lung Adenocarcinoma Cells
100%
A1 Receptor
100%
Mutant Epidermal Growth Factor Receptor
100%
Osimertinib
100%
Epidermal Growth Factor Receptor
62%
Receptor Antagonist
25%
Combination Therapy
25%
Receptor Activation
25%
Pleural Effusion
25%
Lung Adenocarcinoma
25%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
25%
Overexpression
12%
Multiple Lung Metastases
12%
EGFR mutation
12%
Gefitinib
12%
Non-small Cell Lung Cancer (NSCLC)
12%
Clinical Practice
12%
Ligand-receptor Binding
12%
Lung Metastasis
12%
Operative
12%
Right Upper Lobectomy
12%
Old Japanese
12%
Novel Therapeutics
12%
Receptor Tyrosine Kinase
12%
Lung Adenocarcinoma Cells
12%
Japanese Females
12%
Isolated Cells
12%
Tumor Recurrence
12%
Lung Lesions
12%
T790M mutation
12%
L858R
12%
Insulin-like Growth Factor 2 (IGF2)
12%
L858R mutation
12%
Novel Cell Line
12%
Third Generation
12%
Tyrosine Kinase Inhibitor Therapy
12%
Specific Treatment
12%
Late Growth
12%
Inhibitor Combination
12%
Re-biopsy
12%
Medicine and Dentistry
Epidermal Growth Factor Receptor
100%
Lung Adenocarcinoma Cell Line
100%
Somatomedin C Receptor
100%
Osimertinib
100%
Lung Metastasis
25%
Combination Therapy
25%
Pleura Effusion
25%
Lung Adenocarcinoma
25%
Epidermal Growth Factor Receptor Kinase Inhibitor
25%
Biopsy
12%
In Vitro
12%
Cell Line
12%
Gefitinib
12%
Lobectomy
12%
Protein Tyrosine Kinase
12%
Non Small Cell Lung Cancer
12%
Tumor Recurrence
12%
Lung Lesion
12%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Lung Adenocarcinoma
100%
Somatomedin C Receptor
100%
Osimertinib
100%
Lung Metastasis
25%
Combination Therapy
25%
Pleura Effusion
25%
Epidermal Growth Factor Receptor Kinase Inhibitor
25%
Non Small Cell Lung Cancer
12%
Protein Tyrosine Kinase
12%
Gefitinib
12%
Tumor Recurrence
12%
Lung Lesion
12%